tolerated. There did not appear to be anyevidence of a clear safety concern, but there were some important observationspertaining to tolerability in some patients.The most common treatment-emergentadverse event was dose-dependent nau-sea, and this was most notable at the timeof initiating therapy and was reported atlower incidence thereafter. Nausea wasmostly mild or moderate in intensity,with a low incidence of severe nausea(/H110116%) and low withdrawal from the study due to nausea ( /H110113%). Hypoglycemia occurred more readily